Chaffetz and Cummings Investigate Dramatic Price Increases for EpiPens

Chaffetz and Cummings Investigate Dramatic Price Increases for EpiPens

Oversight Committee Requests Documents and Communications Related to Mylan Price Hike

Washington, D.C. (Aug. 29, 2016)—Today, Reps. Jason Chaffetz (R-UT) and Elijah E. Cummings (D-MD), the Chairman and Ranking Member of the House Committee on Oversight and Government Reform, sent a letter to Heather Bresch, the CEO of Mylan, requesting documents and communications regarding the increasing price of EpiPens.

"Mylan has a virtual monopoly over the epinephrine auto-injector market," Chaffetz and Cummings wrote. "While families and schools are struggling to keep up with your company's unreasonable price increases, Mylan has profited richly from its pricing strategy."

Chaffetz and Cummings are requesting documents to better understand the increasing cost of EpiPens, including documents relating to the company's revenues from sales of EpiPens since 2007, manufacturing costs, and the amount of money the company receives from federal government health care programs.

Click here to read today's letter.